We identified transcriptional effects of MEK and SHP2 inhibitors on pathways including epithelial–mesenchymal transition, NFKB signaling, and RAS signaling, the same pathways that are activated in neurofibroma versus control nerve/DRG (Kershner et al, 2022). The gene discussed is MAP2K7; the disease is plexiform neurofibroma.